JAK1 and primary cutaneous T-cell non-Hodgkin lymphoma: The well-known JAK1/2 inhibitor, ruxolitinib, has been evaluated, with an observed clinical benefit rate (CBR; i.e., response lasting > 6 months) of 35%, in a study including both PTCL and cutaneous T-cell lymphoma (CTCL) [81].